Fairmount Funds Management LLC Verona Pharma PLC Transaction History

Fairmount Funds Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$19.41 - $23.43 $53.3 Million - $64.3 Million	-2,745,490 Reduced 87.79%	381,939 $8.07 Million
Q1 2023 May 15, 2023	BUY	$18.06 - $25.27 $4.55 Million - $6.37 Million	251,903 Added 8.76%	3,127,429 $62.8 Million
Q4 2022 Feb 14, 2023	BUY	$9.84 - $26.13 $1.93 Million - $5.14 Million	196,544 Added 7.34%	2,875,526 $75.1 Million
Q3 2022 Nov 09, 2022	BUY	$4.14 - $13.59 $7.25 Million - $23.8 Million	1,752,380 Added 189.12%	2,678,982 $27.4 Million
Q3 2021 Nov 15, 2021	BUY	$5.29 - $6.35 $4.46 Million - $5.35 Million	842,658 Added 1003.83%	926,602 $5.08 Million
Q1 2021 May 14, 2021	SELL	$7.08 - $9.33 $113,676 - $149,802	-16,056 Reduced 16.06%	83,944 $702,000
Q3 2020 Nov 12, 2020	BUY	$4.45 - $10.2 $445,000 - $1.02 Million	100,000 New	100,000 $624,000

167

68.7M

704K

685K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

Stay updated on Fairmount Funds Management LLC with notifications on news.